Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy

Published:2004-12 Issue:12 Volume:89 Page:5910-5915
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:The Journal of Clinical Endocrinology & Metabolism

Author:

Dickinson A. Jane,Vaidya Bijay,Miller Margaret,Coulthard Alan,Perros Petros,Baister Elizabeth,Andrews Christopher D.,Hesse Lutz,Heverhagen Johannes T.,Heufelder Armin E.,Kendall-Taylor Pat

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appraising the Evidence;Copernicus Books;2024

2. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy;European Journal of Endocrinology;2021-10-01

3. Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-κB pathway;PLOS ONE;2021-04-22

4. Teprotumumab: a disease modifying treatment for graves’ orbitopathy;Thyroid Research;2020-07-04

5. Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves’ Orbitopathy;European Thyroid Journal;2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP